STOCK TITAN

Cue Biopharma, Inc. - $CUE STOCK NEWS

Welcome to our dedicated page for Cue Biopharma news (Ticker: $CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cue Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cue Biopharma's position in the market.

Rhea-AI Summary
Cue Biopharma to present two poster presentations at SITC 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
conferences
-
Rhea-AI Summary
Cue Biopharma completes enrollment of patient expansion cohort for CUE-101 trial in combination with pembrolizumab, demonstrating promising clinical efficacy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.83%
Tags
-
Rhea-AI Summary
Cue Biopharma provided a business and financial update for Q2 2023. They presented positive data from ongoing Phase 1 trials of CUE-101 for head and neck squamous cell carcinoma. They also initiated enrollment in the highest dose cohort of the CUE-102 Phase 1 trial for gastric, pancreatic, ovarian, and colorectal cancers. The company reported collaboration revenue of $1.4 million and $26,000 for Q2 2023 and 2022, respectively. Research and development expenses were $10.7 million and $9.6 million for Q2 2023 and 2022, respectively. General and administrative expenses were $4.3 million and $3.8 million for Q2 2023 and 2022, respectively. As of June 30, 2023, the company had approximately $57.9 million in cash, cash equivalents, and marketable securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.26%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
conferences
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
conferences
-
Rhea-AI Summary
Cue Biopharma announced positive data from Phase 1 clinical trials of CUE-101 for HPV16+ head and neck cancer. Nine out of 14 patients showed tumor regression, with 5 confirmed partial responses and 3 durable stable disease responses. Patients treated with CUE-101 and pembrolizumab had an overall response rate of ~40% and a median duration of response of 35 weeks. CUE-101 as monotherapy demonstrated a median overall survival of nearly 14 months, longer than the current standard of care. The clinical data supports potential registrational paths for both CUE-101 as a monotherapy and in combination with pembrolizumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
Cue Biopharma, Inc.

Nasdaq:CUE

CUE Rankings

CUE Stock Data

103.61M
45.38M
2.97%
32.9%
8.64%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
BOSTON

About CUE

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci